MedPath

Osteoarthritis in Older Adults: Recovery of Mobility and Pain With a Topical Analgesic

Phase 3
Withdrawn
Conditions
Knee Osteoarthritis
Interventions
Drug: Biofreeze
Other: Placebo
Registration Number
NCT01565070
Lead Sponsor
University of Chile
Brief Summary

Biofreeze® is a topical ointment that has menthol and alcamphor. Its analgesic effect lies in the stimulation of A and C fibers by cold and nociceptive stimulation, respectively, which is produced by menthol, apparently through the newly discovered receptor TRPM8 (Transient Receptor Potential melastatin-8) The aim of this study is to investigate if BIOFREEZE ® treatment (Performance Health Inc., Export, PA) improves symptoms associated with moderate knee osteoarthritis, which would decrease the immobility and isolation in older adults.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Moderate osteoarthritis of the knee
  • Age 60 to 80 years
  • Ambulatory
Exclusion Criteria
  • Other conditions that affect mobility
  • Severe chronic diseases such as cardiac or renal failure
  • Cancer
  • Presence of gout
  • Cognitive impairment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BiofreezeBiofreeze-
PlaceboPlaceboUse of placebo ointment
Primary Outcome Measures
NameTimeMethod
WOMAC score60 days

WOMAC score corresponds to Western Ontario and McMaster Universities Index of Osteoarthritis

Secondary Outcome Measures
NameTimeMethod
Quality of life measured using SF 3660 days

SF 36 correponds to a health related quality of life score

Trial Locations

Locations (1)

Institute of Nutrition and Food Technology

🇨🇱

Santiago, Met, Chile

Institute of Nutrition and Food Technology
🇨🇱Santiago, Met, Chile

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.